Taken together, our in vitro and in vivo efficacy data demonstrate that targeting p300/CBP proteins for degradation using CBPD-409 represents a promising therapeutic strategy for advanced AR-dependent prostate cancers, while exhibiting minimal on or off-target toxicity. Here, EP300 is linked to prostate cancer.